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Rho GTPases are overexpressed in a variety of human tumors contributing to both tumor
proliferation and metastasis. Recently, several studies demonstrate an essential role of transcrip-
tional regulation in Rho GTPases-induced oncogenesis. Herein, we demonstrate that RhoA, Rac1,
and Cdc42 promote the expression of cyclooxygenase-2 (COX-2) at the transcriptional level by a
mechanism that is dependent on the transcription factor nuclear factor-B (NF-B), but not Stat3,
a transcription factor required for RhoA-induced tumorigenesis. With respect to RhoA, this effect
is dependent on ROCK, but not PKN. Treatment of RhoA-, Rac1-, and Cdc42-transformed
epithelial cells with Sulindac and NS-398, two well-characterized nonsteroid antiinflammatory
drugs (NSAIDs), results in growth inhibition as determined by cell proliferation assays. Accord-
ingly, tumor growth of RhoA-expressing epithelial cells in syngeneic mice is strongly inhibited by
NS-398 treatment. The effect of NSAIDs over RhoA-induced tumor growth is not exclusively
dependent on COX-2 because DNA-binding of NF-B is also abolished upon NSAIDs treatment,
resulting in complete loss of COX-2 expression. Finally, treatment of RhoA-transformed cells with
Bay11-7083, a specific NF-B inhibitor, leads to inhibition of cell proliferation. We suggest that
treatment of human tumors that overexpress Rho GTPases with NSAIDs and drugs that target
NF-B could constitute a valid antitumoral strategy.
INTRODUCTION
Rho GTPases are a multimember family of proteins involved
in diverse cellular functions that relate to cell growth, de-
velopment, apoptosis, tumorigenesis, and metastasis (Van
Aelst and D’Souza-Schorey, 1997; Bar-Sagi and Hall, 2000;
Aznar and Lacal, 2001a,b, 2003; Ridley, 2001; Schmitz et al.
2002). Rho proteins regulate transcription via several tran-
scription factors that include SRF, NF-B, E2F, Stat3, Stat5a,
Pax6, FHL-2, Estrogen Receptor /, ELK, PEA3, ATF2,
MEF2A, Max, and CHOP/GADD153 (Aznar and Lacal,
2001b).
When overexpressed, Rho GTPases are tumorigeneic and
transform murine fibroblast to promote in vivo tumor
growth and distant lung metastasis in syngeneic mice (Pe-
rona et al., 1993; van Leeuwen et al., 1995; del Peso et al.,
1997). As well, they mediate many aspects of the oncogenic-
ity of several oncogenes such as Ras, Met, EGFR, and IGFR
(Qiu et al., 1995a,b; Nur-E-Kamal et al., 1999; Boerner et al.,
2000; Sachdev et al., 2001). Overexpression or deregulation
of the GTPase or some element of the Rho pathway has been
reported for human breast, colon, head and neck squamous
carcinomas; and testicular germ, ovarian, leukemias, osteo-
sarcomas, gastric, thyroid papillary, prostate, and hepatocel-
lular cancer, among others (reviewed in Aznar and Lacal,
2003).
The role of transcription in promoting the tumoral and
metastatic phenotype of Rho GTPases is acquiring increased
attention. We have recently described that activation of Stat3
is involved in transformation of human fibroblasts by onco-
genic RhoA (Benitah et al., 2003). Furthermore, we have
identified Stat5a as an essential component of RhoA-in-
duced epithelial to mesenchymal transition and cell motility
(Aznar et al., 2002). Transcription of cyclin D1 and the proto-
oncogene c-myc takes place by a Rho-dependent mechanism
that permits G1 entry (Danen et al., 2000; Chiariello et al.,
2001; Welsh et al., 2001). Finally, an indirect role for both
nuclear factor-B (NF-B) in RhoGEF-mediated tumorigen-
esis, and for FHL2 in Rho-dependent tumor progression of
prostate cancer, has been proposed (Whitehead et al., 1999;
Muller et al., 2002). With respect to the metastatic phenotype,
transcription and expression of the uPAR gene is dependent
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on RhoA upon integrin signaling, and SRF is regulated by
changes in actin dynamics to promote transcription of vin-
culin and actin, both necessary for the cytoskeletal changes
essential to motility and invasion (Sotiropoulos et al., 1999;
Muller et al., 2000, 2002; Psichari et al., 2002). However, little
is known on the target genes regulated by these transcrip-
tion factors that allow proper tumor progression in the
context of Rho GTPases.
Herein, we demonstrate that Rho GTPases induce cyclo-
oxygenase-2 (COX-2) expression in epithelial cells by a NF-
B–dependent mechanism. COX-1 and COX-2 catalyze the
synthesis of prostaglandins (Gupta and Dubois, 2001).
Whereas COX-1 is constitutively expressed in most tissues
and maintains housekeeping prostaglandin synthesis,
COX-2 is inducible upon proinflammatory cytokines,
growth factors, and oncogenes (Dubois, 2001; Gupta and
Dubois, 2001). Accordingly, tumor cells that express COX-2
secrete proangiogenic factors stimulating tube formation
and endothelial migration, contributing to the vasculariza-
tion and growth of the tumor (Tsujii et al., 1998; Cao and
Prescott, 2002). COX-2 is tumorigenic because its overex-
pression in the mammary glands itself causes malignant
growth and metastasis in transgenic mice (Liu et al., 2001).
At last, several human tumors including colon, breast, pan-
creas, lung, and squamous cell carcinoma of the head and
neck display high levels of COX-2 protein (Tegeder et al.,
2001).
COX-2 has acquired great interest as a potential target for
the prevention and treatment of several human cancers.
Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit
COX-2 are potent antitumoral and antimetastatic agents in
vivo against several tumor models (Tegeder et al., 2001).
However, these drugs display COX-2 independent effects
that mainly affect activator protein-1, mitogen-activated pro-
tein kinase, and NF-B (Tegeder et al., 2001). Consequently,
the promiscuity of NSAIDs has led to the development of
new COX-2 inhibitors, termed Coxibs (celecoxib and rofe-
coxib) with very selective COX-2 inhibitory capacity, albeit,
their specificity has been recently challenged (Jones et al.,
1999; Tegeder et al., 2001).
Herein, we provide evidence that indicates that treatment
of Rho-bearing tumors with NSAIDs and drugs that target
NF-B may constitute a valid cancer therapy.
MATERIALS AND METHODS
Cell Culture, Transfections, and NSAIDs Treatment
Madin-Darby canine kidney (MDCK) epithelial cells, human colo-
rectal carcinoma cells HT29 and DLD1 were cultured in DMEM
supplemented with 10% fetal bovine serum and 1 mM glutamine.
NIH3T3 fibroblasts were cultured in DMEM supplemented with 5%
newborn calf serum and 1 mM glutamine. For transient expression
assays, 2  105 cells were transfected in six-well dishes by Lipo-
fectAMINE Plus method as described by the manufacturer (Invitro-
gen, Carlsbad, CA). The amount of plasmidic DNA was kept con-
stant at 3–5 g/33-mm plate with the corresponding empty vector,
and 0.5 g of reporter was transfected where indicated. For stable
expression, cells were transfected as indicated above and 48 h
posttransfection selection was added. For pcDNAIIIb, RhoAQL,
Rac1QL, Cdc42QL, Rac1N17, and Cdc42N17, selection was carried
out with 750 g/ml G418 (Sigma-Aldrich, St. Louis, MO). Sulindac
and NS-398 were purchased from LKT Laboratories (Ann Arbor,
MI) and Cayman Chemical (Ann Arbor, MI), respectively. Both
NSAIDs were diluted to the indicated concentrations and medium
was added fresh each 48 h. A 50 mM stock solution of Bay11-7083
(Calbiochem, San Diego, CA) was prepared and later used at a final
concentration of 10 M in DMEM.
Plasmids
PCDNAIIIB plasmid (Invitrogen) and derived expression vectors
encoding for constitutively activated RhoA (QL), Rac1 (QL), and
Cdc42Hs (QL) proteins and their wild-type versions have been
described previously (Aznar et al., 2001). The HIV-Luc reporter that
contains NF-B-responsive elements has been described (Aznar et
al., 2001). PRCCMV-p65 and pRCCMV-IB A32/36S, wild-type and
dominant negative pCEFL-Stat3 constructs, have been described
previously (Aznar et al., 2001). COX-2-Luc reporter vector contain-
ing the promoter sequence spanning from nucleotide1778 to107
of human COX-2 gene was kindly provided by Dr. Mun˜oz Salas
(Diaz-Cazorla et al., 1999). Wild-type and dominant negative
(deltaF3) pRCCMV-FLAG-PKN constructs were kindly provided by
Dr. Ono (Biosignal Research Center and Graduate School of Science
and Technology, Kobe University, Japan). Wild-type and dominant
negative (KD-IA) pCAG-myc-ROCK constructs were a kind gift of
Dr. Narumiya (Department of Pharmacology, Kyoto University,
Faculty of Medicine, Kyoto, Japan).
Gene Expression Analysis
Cells (2  105) were transfected with the indicated plasmids. Forty-
eight hours after transfection protein extracts were prepared by lysis
with the commercially available Reporter lysis buffer (Promega,
Madison, WI). Protein (0.5–2 g) was assayed for luciferase activity
by using a commercial kit as described by the manufacturer (Pro-
mega). Transfection efficiencies were corrected by detection of the
expressed proteins by Western immunoblotting and with a consti-
tutive RSV5-CAT reporter vector as indicated previously (Aznar et
al., 2001).
Western Blot Assays and Antibodies
For protein expression assays, cells were transfected with the cor-
responding plasmids and incubated in DMEM 0.5% fetal bovine
serum or 10% fetal bovine serum where indicated for the next 48 h.
Preparation of the samples was carried out as described previously
(Benitah et al., 2003). After transfer of proteins to Immobilon-P
polyvinylidene difluoride membrane (Millipore, Bedford, MA), the
blots were incubated with the corresponding antibodies, and im-
munocomplexes were visualized by enhanced chemiluminescence
detection (Amersham Biosciences, Piscataway, NJ) by using either
an anti-rabbit and anti-mouse antibody conjugated to peroxidase
(Santa Cruz Biotechnology, Santa Cruz, CA). -COX-2 and -Cdc42
monoclonal antibodies were purchased to BD Biosciences (San Jose,
CA). -COX1, -p65, and -RhoA were purchased to Santa Cruz
Biotechnology. Anti-Rac1 was purchased to Upstate Biotechnology
(Lake Placid, NY). Anti-Stat3 and anti-phosphoStat3 (Tyr 705) were
purchased to Cell Signaling Technology (Beverly, MA). Mouse
monoclonal anti-phospho-p44/42 mitogen-activated protein kinase
(Thr202/Tyr204) and phospho-MEK1 were purchased from New
England Biolabs (Beverly, MA). Anti-FLAG and anti-myc antibodies
to detect the expression of PKN and ROCK were purchased from
Santa Cruz Biotechnology.
Electrophoretic Mobility Shift Assays (EMSAs)
For EMSA assays, cells were either transfected with the correspond-
ing plasmids or indicated treatments and incubated in appropriate
medium for 24–36 h. Nuclear extracts were obtained as described
previously (Benitah et al., 2003). Briefly, 2 g of nuclear protein was
incubated with 0.1 ng of B probe (5000 cpm) or with unlabeled
probe and subjected to electrophoresis (80 V, 45 min) on a nonde-
naturing 4% acrylamide/bisacrylamide gel (29:1) (Bio-Rad, Her-
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cules, CA). For gel supershift analysis, the nuclear extract was
incubated for 10 min (room temperature) with anti-p65 or anti-p50
(Santa Cruz Biotechnology) in ice before addition of the labeled
probe. For nonspecific competition, Stat3-binding element hSIE
from the c-fos promoter was used.
Anchorage-independent Growth in Soft Agar
Cells (3 103; MDCK or RhoAQL stable clones) in 60-mm dishes were
trypsinized and resuspended in fresh medium. Anchorage-indepen-
dent growth assay was performed as described previously by plating
5000 cells/60-mm dish (Aznar et al., 2001). After 3 wk of incubation the
medium was absorbed, 500 l of 0.005% crystal violet was added and
incubated for 1 h at 37°C. Plates were then washed once with 1
phosphate-buffered saline and visualized under a microscope.
Cell Cytometry and Cell Proliferation Assays
For cell proliferation assays, 1500 cells were seeded in 24-well dishes
and 24 h later the indicated drugs were added to fresh medium. At
the indicated time points, cells were washed, fixed on 1% glutaral-
dehyde (500 l) for 30 min, and washed three times with 1
Figure 1. Rho GTPases induce the expression of COX-2 in NIH3T3, HT29, DLD-1, and MDCK cells. (A) Transient expression of RhoA, Rac1,
and Cdc42 (wt and QL) induce the expression of COX-2 in NIH3T3 cells compared with empty vector (pcDNAIIIb) transfected cells. (B)
Transient expression of RhoAQL, Rac1QL, and Cdc42QL increases the expression of COX-2 in HT29 human colorectal cell line, compared
with HT29-pcDNAIIIb transfected cells. (C) Transient expression of wild-type and oncogenic RhoA and Cdc42 induces the expression of
COX-2 in MDCK epithelial cells compared with empty vector transfected cells. For A, B, and C, all cell lines were transfected as indicated
in MATERIALS AND METHODS and whole cell lysates were obtained 48 h posttransfection. (D) Stable MDCK-RhoAQL, Rac1QL, and
Cdc42QL cell lines exhibit high expression of COX-2 with respect to stable MDCK-pcDNAIIIB cells. (E) RhoAQL, Rac1QL, and Cdc42QL do
not stimulate the expression of COX-1 in MDCK (same extracts as in D) or NIH3T3 cells (same extracts as in A). (F) Stable HT29 transfectants
of dominant negative Cdc42 (N17) (left), but not Rac1N17 (middle), display a complete loss of COX-2 expression compared with control
empty vector transfected parental cell line. Transient expression of dominant negative RhoA (N19) does not inhibit COX-2 expression in HT29 cells
(right). (G) RhoAQL, but not Cdc42, induces the expression of COX-2 in human colorectal cell line DLD1, which lack endogenous expression of
COX-2. Equal loading was verified with anti-tubulin in all blots. All experiments were performed at least three independent times.
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phosphate-buffered saline. Once all time points were collected, 500
l of 0.1% crystal violet was added to cells for 30 min and then
washed as described above. To obtain the incorporated crystal violet
500 l of 10% acetic acid was added for 10 min and was later
collected and read at a wavelength of 595 nm. For cell cytometry
analysis, 2  105 cells were plated on 60-mm dishes and were
treated with sulindac or NS-398 for the indicated time. For FACS-
SCAN analysis, the protocol was followed as described previously
(Embade et al., 2000). Adhered cells were trypsinized and the cell
membrane was permeabilized with 70% ethanol, spun, and resus-
pended in propidium iodide.
In Vivo Tumorigenic Assay and NSAIDs Treatment
Cells (2  106) were trypsinized and resuspended in 100 l of fresh
DMEM medium. Cells were injected subcutaneously in the limb and
tumor growth was monitored twice a week for 90 d. Tumor volume
was determined using the following equation: V  (Dxd2)/2. When
tumors had reached a volume of 0.1 cm3, 3 mg/kg NS-398 was
injected intraperitoneally three times a week during 9 wk. Tumor
volume was measured at 2-d intervals during the treatment.
Prostaglandin E2 (PGE2) Quantification
Cells (5000) were plated on 24-well dishes and 24 h later they were
treated with Bay11-7083 (10 M) at the indicated time intervals (6,
8, 12, and 24 h) to collect all the supernatants at the same time of
analysis. The amount of PGE2 was measured using the commercial
kit PGE2 EIA kit-monoclonal (Cayman Chemical) as described by
the manufacturer. Medium (50 l) was collected and mixed in a
PGE2 monoclonal antibody-coated 96-well dish and incubated over-
night for 18 h at 4°C. The wells were then washed five times and
incubated with Ellman’s reagent in the dark for 90 min at room
temperature. The assay was read at a single wavelength of 405 nm.
RESULTS
Oncogenic RhoA, Rac1, and Cdc42 Induce the
Expression of COX-2 in NIH3T3, HT29, and MDCK
Cells
We ectopically expressed pCDNAIIIb or derived expression
vectors encoding for RhoA, Rac1, and Cdc42 in NIH3T3
fibroblasts, HT29 human colorectal carcinoma cells, and
MDCK epithelial cells. Wild-type and oncogenic version of
all three GTPases induced high levels of COX-2 in NIH3T3
with respect to pcDNAIIIb control transfected cells (Figure
1A). In addition, oncogenic RhoA, Rac1, and Cdc42 (QL)
increase the high endogenous level of COX-2 in HT29 com-
pared with empty vector transfected cells (Figure 1B). With
respect to MDCK cells, transient expression of both RhoA
and Cdc42 (QL and wt) induced COX-2 expression when
compared with MDCK-pcDNAIIIb cells (Figure 1C). How-
ever, we were not able to obtain significant transient expres-
sion of Rac1QL in MDCK cells as determined by Western
immunoblot, nor Rac1-dependent effects such as SRF or
NF-B transcriptional activation. Thus, we sought to verify
whether Rac1QL regulates COX-2 levels in MDCK cells by
stable expression. In this sense, we generated MDCK stable
transfectants of pcDNAIIIb or its derived vector encoding
for Rac1QL, and verified the level of COX-2 expression. We
were able to select six independent Rac1QL-expressing
clones that exhibited increased levels of Rac1QL and that
induced high COX-2 expression of which three representa-
tive ones are shown (Figure 1D). Additionally, we generated
MDCK stable transfectants of vectors encoding for RhoA
and Cdc42QL, and tested for the level of COX-2 expression
for three independent clones of each GTPase. Two represen-
tative RhoAQL clones SP7.3, SP7.4, and a mass culture
(SP7.29) that express different amounts of oncogenic RhoA,
exhibit differential expression of COX-2 with respect to
MDCK control cells, SP7.0. The same effect was observed
with two independent Cdc42-expressing clones, SP7.18 and
SP7.17, and a mass culture (SP7.20). Thus, RhoA, Rac1, and
Cdc42 (QL) induce high levels of COX-2 also in MDCK cells.
In addition, we verified that this effect was specific to
COX-2 and not the constitutively expressed isoform COX-1
(Figure 1E). SP7.0 (MDCK-pcDNAIIIb control) and cells that
express high levels of each GTPase, SP7.29 (RhoAQL), SP7.9
(Rac1QL), and SP7.18 (Cdc42QL) were used to verify COX-1
expression. As seen in Figure 1E the levels of COX-1 remain
unchanged upon Rho GTPases expression in MDCK cells.
The same results were obtained with all RhoAQL-, Rac1QL-,
Figure 2 (facing page). Rho GTPase-dependent expression of
COX-2 is at the transcriptional level and dependent on NF-B. (A)
RhoA, Rac1, and Cdc42 (QL) induce the transcription of the proxi-
mal region of the cox-2 promoter (1772 to 106) in MDCK cells.
Stable cell lines of RhoAQL, Rac1QL, and Cdc42QL (7.3, 7.9, and
7.18, respectively) were transfected with COX2-Luc reporter vector
(0.5 g), and luciferase activity was measured 48 h posttransfection.
Data shown represents a single experiment performed in tripli-
cate  SD. (B) IBS32/36A inhibits RhoA- and Cdc42QL-induced
COX-2 expression. Transient transfection of 2 g of IBS32/36A
(IBdp) together with 1 g of pcDNAIIIb, RhoAQL, or Cdc42QL
was carried out in MDCK cells and extracts for Western blot anal-
ysis were obtained 48 h posttransfection. (C) IBS32/36A inhibits
Rac1QL-induced COX-2 expression in MDCK cells. MDCK-pcD-
NAIIIb or clone SP7.9 (MDCK-Rac1QL) were transiently transfected
with IBS32/36A (2 g), and Western blot analysis was carried out
48 h posttransfection. Equal loading was verified with an anti-
tubulin antibody. (D) IBS32/36A inhibits transcription of the
cox-2 promoter induced by RhoAQL, Rac1QL, and Cdc42QL. COX2-
Luc (0.5 g) and IBS32/36A (1.0 g) were transiently cotrans-
fected in 7.0 (MDCK-pcDNAIIIb), 7.3 (MDCK-RhoAQL), 7.9
(MDCK-Rac1QL), and 7.18 (MDCK-Cdc42QL), and luciferase activ-
ity was measured 48 h posttransfection (E) Expression of IBS32/
36A leads to a functional inhibition of NF-B transcriptional activity
in MDCK cells. Same experiment as in D was carried out with 0.5 g
of HIV-luc reporter instead of COX-2-luc, and luciferase activity
was measured 48 h posttransfection. Data shown in D and E rep-
resent a single experiment performed in triplicate  SD. (F) Over-
expression of p65 augments COX-2 expression in RhoAQL- and
Cdc42QL-expressing cells. MDCK cells were transfected with 2.0 g
of p65 together with pcDNAIIIB (1.0 g) (referred as control cells)
RhoAQL (1.0 g) or Cdc42QL (1.0 g), and extracts were obtained
48 h posttransfection. (G) p65 potentiates COX-2 expression in SP7.7
(Rac1QL-MDCK) clone without any effect in parental MDCK cells.
p65 (2.0 g) was transfected in MDCK-pcDNAIIIB control cells, or
in SP7.7 cells and extracts were obtained 48 h posttransfection.
Expression of p65 was verified in F and G with an anti-p65 anti-
body. Equal loading was determined with anti-tubulin. (H) Expres-
sion of p65 produces a synergism in Rho-mediated transcription of
the cox-2 promoter. (I) Expression of p65 in MDCK cells together
with RhoAQL, Rac1QL, or Cdc42QL leads to a functional increase of
NF-B transcriptional activity. For parts H and I transfection was
carried out as indicated in parts D and E, but cotransfecting p65
rather than IBS32/36A. Transfection efficiencies in D, E, H, and I
were normalized using an RSV5-CAT reporter (0.5 g) transfected
along with the indicated plasmids. All experiments were performed
four times with similar results.
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and Cdc42QL-expressing clones and mass cultures with
identical results (our unpublished data). As well, no change
in COX-1 expression was observed upon transient expres-
sion of RhoAQL, Rac1QL, or Cdc42QL in NIH3T3 cells
compared with empty vector transfected cells (Figure 1E).
As shown in Figure 1B, HT29 human colorectal carcinoma
cells show high endogenous level of COX-2 compared with
other cell systems. We next verified whether Rho GTPases
are involved in the expression of COX-2 in the human colo-
rectal cancer-derived cell line HT29. To that end, we at-
tempted to generate HT29 stable transfectants that express
either dominant negative Rac1 (N17), Cdc42 (N17), RhoA
(N19), or control empty vector (pcDNAIIIb). As observed in
Figure 1F, expression of Cdc42N17 induced a drastic reduc-
tion of COX-2 expression, whereas Rac1N17 expression had
no effect on COX-2 levels. The same result was obtained
with transient expression of Cdc42N17 in HT29 cells, al-
though due to a transfection efficiency of 35%, we did not
observed a full inhibition of COX-2 expression (our unpub-
lished data). Although HT29 cells can transiently express
high levels of dominant negative RhoA (N19), we were not
able to obtain viable clones that expressed dominant nega-
tive RhoA (N19) in a stable manner. Thus, we expressed
RhoA in transient transfection experiments. RhoAN19 did
not affect the expression of COX-2 in HT29 cells (Figure 1F).
As controls of dominant negative activity for each GTPase,
we verified that expression of RhoAN19, Rac1N17 and
Cdc42N17 in HT29 cells inhibited the activation of NF-B
activity by Ost, Vav1, and Dbl, respectively, as described
previously (Montaner et al. (1998)) (our unpublished data).
Because HT29 have a high level of endogenous COX-2
expression, we next investigated whether Rho GTPases were
able to regulate COX-2 expression in another human colo-
rectal cancer-derived cell line such as DLD-1, with low levels
of expression of Rho GTPases and which completely lacks
endogenous COX-2 expression. As shown in Figure 1G,
RhoA efficiently induced the expression of COX-2 in DLD1
cells when expressed ectopically. In contrast, Cdc42 (Figure
1G), and Rac1 (our unpublished data) failed to do so. Thus,
these results suggest that Rho GTPases can modulate COX-2
expression in human colon cancer. However, each GTPase
analyzed in our work seems to have differential contribution
or mechanisms to effect regulation of COX-2.
Rho-A-, Rac1-, and Cdc42-induced Expression of
COX-2 Is Dependent on the NF-B Transcription
Factor
Analysis of the promoter of human COX-2 revealed several
putative binding sites for transcription factors whose activ-
ity is modulated by Rho GTPases. These include NF-B,
SRF, C/EBP, AP-1, c-Myc, and STATs. To quantify the
extent of transcription of the cox-2 gene under Rho signaling
a reporter vector termed COX2-Luc containing the cox-2
promoter region spanning from bases 1772 to 106 was
generated (Diaz-Cazorla et al., 1999). Transient transfection
of 0.5 g of COX2-Luc into 7.0 (MDCK-pcDNAIIIB), 7.3
(MDCK-RhoAQL), 7.9 (MDCK-Rac1QL), and 7.18 (MDCK-
Cdc42QL) clones was carried out and 48 h posttransfection
luciferase activity was measured. All three RhoA, Rac1, and
Cdc42 (QL) induced transcription of the cox-2 promoter
compared with empty vector transfected cells (Figure 2A).
It has been reported that NF-B regulates COX-2 expres-
sion under a variety of circumstances such as inflammation,
hypoxia, bacterial infections, or colorectal cancers (Crofford
et al., 1997; Schmedtje et al., 1997; Lim et al., 2001). Thus, we
verified whether this transcription factor played any role in
the induction of COX-2 by Rho GTPases. First, we tran-
siently expressed dominant positive IB that carries serine
residues 32 and 35 mutated to alanine (IBA32/A36), whose
expression leads to a very efficient inhibition of NF-B, and
verified COX-2 levels under Rho signaling in MDCK cells
(Karin et al., 2002). The induction of COX-2 by ectopic ex-
pression of both RhoAQL and Cdc42QL was drastically
inhibited by IBA32/A36 (Figure 2B). The same result was
obtained with two independent stable clones for RhoAQL
(SP7.3 and SP7.29) and Cdc42QL (SP7.17 and SP7.18) (our
unpublished data). As well, Rac1-dependent induction of
COX-2 relies on the NF-B pathway, because ectopic expres-
sion of dominant positive IB in SP7.7 cells inhibited
COX-2 expression (Figure 2C). These results were also ob-
tained with another clone, SP7.9 (our unpublished data). As
expected, inhibition of Rho GTPases-induced COX-2 expres-
sion by IBA32/A36 was at the level of transcription be-
cause it abrogated COX2-Luc transcription when expressed
in stable clones of each GTPase (Figure 2D). As a control of
dominant positive IBA32/A36 activity, we verified that its
expression led to inhibition of NF-B activity and DNA-
binding induced by Rho GTPases (Figure 2E; our unpub-
lished data).
To further test whether NF-B is involved in the induction
of COX-2 by Rho GTPases, we next expressed the p65 sub-
unit of NF-B together with RhoAQL and Cdc42QL or con-
trol vector in MDCK cells. As seen in Figure 2F, transient
coexpression of p65 with either RhoAQL or Cdc42QL in
MDCK cells potentiated COX-2 expression. The same effect
was observed when p65 was transiently transfected into two
Rac1QL-expressing clones, SP7.7 and SP7.9, whereas over-
expression of NF-B alone in MDCK cells did not cause a
significant elevation of COX-2 expression (Figure 2G; our
unpublished data). Expression of p65 in RhoA, Rac1, or
Cdc42QL stable clones led to an increase in cox-2 promoter
activity by more than threefold compared with their respec-
tive controls (Figure 2H). Accordingly, coexpression of p65
increased NF-B transcriptional activity induced by all three
GTPases (Figure 2I). Thus, NF-B mediates the induction of
COX-2 by oncogenic RhoA, Rac1, and Cdc42 at the tran-
scriptional level.
Induction of COX-2 by RhoGTPases Is Not via
Stat3
Activation of Stat3 by members of the family of RhoGTPases,
such as RhoA and Rac has been described previously (Simon et
al., 2000; Aznar et al., 2001; Faruqi et al., 2001). Furthermore,
Stat3 is necessary for RhoA-induced anchorage independent
growth (Aznar et al., 2001). Because the cox-2 promoter contains
putative Stat-binding elements, we sought to verify whether
Stat3 might act downstream of Rho GTPases to induce COX-2
expression.
To that end, we expressed wild-type Stat3 (wt) or a dom-
inant negative Stat3 with a mutated transactivation domain
(Stat3D), in RhoAQL-, Rac1QL-, and Cdc42QL-expressing
clones SP7.29, SP7.9, and SP7.17 (Figure 3). RhoA QL, Rac1
QL, and Cdc42QL efficiently induced tyrosine-705 phos-
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phorylation of Stat3 in MDCK cells; however, no change in
the level of COX-2 was observed upon transfection of either
Stat3wt or Stat3D compared with vector control transfected
cells. Thus, although the COX-2 promoter contains Stat-
responsive elements, and Stat3 is activated by Rho GTPases
in MDCK epithelial cells, there is no functional relationship
between Stat3 and COX-2 under Rho GTPases signaling.
ROCK, but Not PKN, Is Necessary for RhoA-
induced COX-2 Expression via NF-B
RhoA signaling is dependent on a large number of effector
proteins that physically interact with RhoA and transmit the
signal within the cell. Among the most studied of these are
the families of ROCK and PKN (Van Aelst and D’Souza-
Schorey, 1997). These families of effectors mediate most of
the cytoskeletal changes induced by RhoA and have been
implicated in some of the developmental processes that lead
to growth and metastasis of human tumors by RhoA. Thus,
we next studied the possible role of ROCK and PKN in
RhoA-induced expression of COX-2. To that end, we ex-
pressed either ROCKwt or dominant negative ROCKdn in
RhoAQL-expressing cells or MDCK parental cells, and mea-
sured the protein level of COX-2. Although expression of
ROCKwt synergized with RhoA to induce expression of
COX-2, ROCKdn greatly impaired COX-2 expression (Fig-
ure 4A). This effect was specific to RhoA signaling because
overexpression of ROCKwt or ROCKdn in parental MDCK
cells had no effect over COX-2 expression (Figure 4A). No
effect of ROCK on COX-2 expression was observed in
MDCK parental cells (Figure 4A). Inhibition of COX-2 ex-
pression was also observed when RhoAQL-expressing cells
were treated with Y-27632, a specific inhibitor of ROCK
kinases (Figure 4B).
As shown above, expression of COX-2 induced by RhoA is
at the transcriptional level via the NF-B pathway. Thus, we
next verified whether ROCK was involved in this process.
The COX2-Luc reporter vector was transfected in MDCK-
RhoAQL cells together with control vector, ROCKwt, or
ROCKdn and transcription of the COX-2 promoter was mea-
sured. As well, MDCK-RhoAQL cells transfected with the
COX2-Luc reporter were treated with Y-27632 (10 M) for
24 h. Although expression of ROCKwt resulted in a moder-
ate increase in transcription of the COX-2 proximal pro-
moter region, expression ROCKdn or treatment with
Y-27632 inhibited such transcription (Figure 4C). The same
type of experiment was carried out with the NF-B–respon-
sive reporter vector HIV-luc, to verify whether ROCK had
any effect over NF-B activity. Surprisingly, expression of
ROCKwt or ROCKdn, or treatment with Y-27632 had the
same effect over NF-B activity than COX-2 promoter tran-
scription.
The same experiments as described above were carried
out with respect to PKN. However, expression of PKNwt of
PKNdn in RhoAQL-transformed cells had no effect over
COX-2 expression (Figure 4E). As well, no changes in the
transcription of the COX-2 promoter were observed between
MDCK cells transfected with RhoAQL or cotransfected with
RhoAQL and PKNwt or PKNdn (Figure 4F). Expression of
FLAG-tagged PKN and myc-tagged ROCK constructs were
verified using anti-FLAG and anti-myc antibodies, respec-
tively (Figure 4, A and E).
Thus, ROCK, but not PKN, affects RhoA-mediated COX-2
expression at the transcriptional level via modulation of the
activity of NF-B. To our knowledge, this is the first evi-
dence for a relationship between NF-B and ROCK kinases.
Nonsteroidal NSAIDs Inhibit Both Proliferation and
Tumor Growth of RhoAQL Epithelial Cells
Given the implication of COX-2 and Rho GTPases overex-
pression in tumorigenesis and metastasis of human tumors,
the above-mentioned results suggest that COX-2 might play
a role in RhoA-mediated tumorigenesis. First, we analyzed
the tumorigenic potential of stable MDCK-RhoAQL trans-
fectants. Four different RhoAQL expressing clones were
plated on soft agar to determine their capacity to grow
under anchorage-independent conditions compared with
MDCK-pcDNAIIIb (negative control) and MDCK-K-RasV12
cells (positive control). Although MDCK-pcDNAIIIb cells do
not grow under these conditions, all MDCK-RhoAQL clones
displayed anchorage-independent growth. Both the growth
rate and size of RhoAQL clones in all cases was lower and
smaller, respectively, compared with MDCK-K-RasV12
clones. Representative pictures of RhoAQL and K-RasV12
clones are shown in Figure 5A. Accordingly, four mice were
injected with 2  106 MDCK-RhoAQL (SP7.3 and SP7.29)
cells and tumor growth was monitored weekly up to 90 d
after injection. As controls, MDCK-pcDNAIIIb and MDCK-
KrasV12 cells were injected in the same conditions. Al-
though control MDCK-pcDNAIIIb cells did not induce any
detectable tumor, K-RasV12 cells developed tumors in 100%
of injected mice approximately 10 to 15 d after injection.
Both MDCK-RhoAQL clones (SP7.3 and SP7.29) induced
tumor growth in three of four animals (75%). However, both
the tumor volume and growth rate of RhoAQL clones were
significantly lower than that displayed by K-RasV12 cells
because RhoAQL tumors reached a size similar to K-RasV12
tumors 30 d after injection, with tumor volumes ranging 1
cm3 after 2 mo of inoculation. Representative pictures of
MDCK-RhoAQL induced tumors are shown in Figure 5B.
We next verified whether RhoAQL clones were suscepti-
ble to growth inhibition upon treatment with two NSAIDs,
sulindac and NS-398. MDCK, MDCK-K-RasV12, and
MDCK-RhoAQL (SP7.29) cells were treated with increasing
amounts of Sulindac or NS-398, and cell viability was
measured at 24-h intervals up to 4 d (Figure 5, C and D).
Figure 3. Stat3 transcription factor is not involved in the expres-
sion of COX-2 under Rho GTPases signaling. Activation of Stat3 and
Stat3 expression were determined using an anti-Stat3PY-694 and
anti-Stat3 antibody respectively. Equal loading was verified with
anti-tubulin. Results shown are representative of five independent
experiments.
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A slight, nonsignificant decrease in cell growth was ob-
served on MDCK-pcDNAIIIb cells upon treatment with
both NSAIDs. However, in keeping with previous publi-
cations (Taylor et al., 2000), K-RasV12-expressing cells
were significantly more sensitive to sulindac and NS-398.
RhoAQL-expressing cells were also highly sensitive to
sulindac and NS-398 treatment as early as 24 h upon
treatment. Inhibition of proliferation was observed at con-
centrations of 50 M for NS-398 and 100 M for sulindac,
with strong inhibition at 100 and 200 M, respectively
(Figure 5, C and D). However, maximal inhibition was
achieved at concentrations of 150 and 400 M for NS-398
and sulindac, respectively. Inhibition of cell proliferation
with both NSAIDS was also observed upon treatment of
MDCK-Rac1QL and MDCK-Cdc42QL cells at the same
concentrations as those used for RhoAQL.
The growth inhibitory action of both drugs over RhoAQL-
expressing cells versus control MDCK cells was due to
strong induction of apoptosis rather than a cell cycle arrest
as determined by flow cytometry. MDCK and RhoAQL cells
Figure 4. ROCK, but not PKN, is
involved in RhoA-mediated COX-2
expression and NF-B transcrip-
tional activity. (A) ROCKwt and
ROCKdn synergize and inhibit, re-
spectively, RhoAQL-induced COX-2
expression (right) without any effect
over COX-2 expression in parental
MDKC-pcDNAIIIb cells (left).
ROCKwt and ROCKdn (2.0 g
each) were cotransfected with pcD-
NAIIIb or RhoAQL in MDCK cells
and whole cell extracts were col-
lected 48 h posttransfection and sub-
jected to Western blot analysis. Ex-
pression of ROCKwt and ROCKdn
were verified with anti-myc anti-
body. (B) Y-27632 inhibits COX-2 ex-
pression induced by RhoAQL.
MDCK-RhoAQL cells were treated
with Y-27632 (10 M) for 24 h, and
whole cell extracts were then ob-
tained and used to verify COX-2 ex-
pression. (C and D) ROCK is neces-
sary for both RhoA-induced
transcription of the cox2 proximal
promoter region and NF-B tran-
scriptional activation. COX2-Luc or
HIV-luc (0.5 g) was cotransfected
with ROCKwt or ROCKdn in
MDCK cells along with empty vec-
tor or RhoAQL. Twenty-four hours
posttransfection, luciferase activity
was measured. As well, RhoAQL
transfected cells were treated with
Y-27632 (10 M) for 24 h and lucif-
erase activity was measured at this
time. (E) PKN is not necessary for
RhoAQL-induced COX-2 expres-
sion in MDCK cells. PKNwt or
PKNdn (2.0 g) were transfected
into MDCK cells along with pcD-
NAIIIb or RhoAQL vectors, and 48 h
posttransfection whole cell extracts
were obtained. Expression of FLAG-
PKNwt and FLAG-PKNdn was ver-
ified using an anti-FLAG antibody.
(F) PKN has no effect overtranscrip-
tion of the cox2 promoter under
RhoA signaling. MDCK-RhoAQL
cells were transfected either with
empty vector or PKNwt and
PKNdn along with the COX2-luc re-
porter vector. Twenty-four hours
posttransfection, luciferase activity was measured as described in MATERIALS AND METHODS. Results shown in all parts are representative of three
independent experiments.
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were treated with sulindac (400 M) and NS-398 (150 M)
for 120 h and analysis of propidium iodide incorporation by
flow cytometry was carried out at 24-h intervals. Figure 5E
shows a representative histogram at 96 h of NS-398 treat-
ment of MDCK and MDCK-RhoAQL cells. Although control
MDCK cells exhibited a residual 13.79% of apoptosis at 96 h
of treatment with NS-398, 45% of RhoAQL cells were
undergoing apoptosis. Although a higher toxicity was ob-
served with sulindac in MDCK control cells, a strong induc-
tion of apoptosis was observed in RhoAQL expressing
clones upon sulindac treatment (our unpublished data).
In addition, the capacity of NS-398 to inhibit RhoAQL-
induced tumor growth in vivo was studied. To this end, 12
mice were injected with MDCK-RhoAQL (SP7.29) cells and
when tumors had reached a mean volume of 0.05–0.1 cm3
(approximately 1 mo after inoculation), mice were treated
intraperitoneally with either NS-398 (3 mg/kg, 3 times a
week during 4 wk) or vehicle, and tumor growth was com-
pared between both populations. As observed in Figure 6A,
a strong tumor growth inhibition was obtained in NS-398–
treated mice that was statistically significant after 1 wk of
treatment (p 0.05). A slight decrease in tumor volume was
observed at this time, yet tumor size was maintained all
throughout the time of treatment after this first week. A
representative picture of a treated and a nontreated mouse is
depicted in Figure 6B. Therefore, NS-398 is a very efficient
antitumoral agent against tumors that arise as a consequence
of RhoAQL overexpression.
Figure 5. Sulindac and NS-398 inhibit proliferation and induce apoptosis of RhoAQL-, Rac1QL-, Cdc42QL-, and KrasV12-expressing
epithelial cells. (A) RhoAQL and KrasV12 promote anchorage independent growth in MDCK cells. (B) RhoAQL promotes tumor growth in
vivo. MDCK or MDCK-RhoAQL cells (2  106) were inoculated subcutaneously in athymic mice, and tumor volume was monitored at 2-d
intervals. Pictures were taken 60 d upon inoculation. (C and D) Indicated concentrations of sulindac or NS-398 inhibit proliferation of MDCK
cells transformed with RhoAQL, Rac1QL, Cdc42QL, and MDCK-RasV12 cells with no significant effect on MDCK parental cells. (E) NS-398
induces apoptosis of MDCK-RhoAQL but not MDCK parental cells. NS-398 (150 M) was added to MDCK-pcDNAIIIb or MDCK-RhoAQL,
and cells were treated for 96 h. At this point, cells were collected by trypsin treatment and were stained with propidium iodide for
fluorescence-activated cell sorting analysis (see MATERIALS AND METHODS).
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Overexpression of members of the family of Rho GTPases
in diverse human tumors has been described. Moreover, in
several tumoral models, Rho GTPases have been found to be
essential either for tumor growth or metastasis. Thus, we
next evaluated whether inhibition of Rho GTPases in human
colorectal carcinoma-derived cell line HT29, which overex-
press both Cdc42 and RhoA, would have any effect over
their capacity to promote tumor growth in vivo. As men-
tioned above, we could not obtain viable stable RhoAN19-
HT29 clones; however, we established two HT29-Cdc42N17
clones (SP1.19 and SP1.21), which have completely lost ex-
pression of COX-2 (Figure 1F). Both HT29-Cdc42N17 stable
cell lines showed an approximate 50% reduction with re-
spect to vector transfected HT29 cells in their capability to
grow under anchorage independent conditions in soft agar
(Figure 6C). Furthermore, both SP1.19 and SP1.21 clones
were injected each in four nude mice and tumor growth was
monitored at 3-d intervals compared with control vector
transfected HT29 cells (SP1.7). Tumor growth of HT29-
Cdc42N17 cells (clones SP1.19) was significantly delayed
compared with that of parental HT29 cells (SP1.7), with
statistical significance (p 0.05) (Figure 6D). Thus, Cdc42 is
an important signaling component that contributes to tumor
growth of HT29 human colorectal carcinoma cells.
NF-B Activity Is Affected by Both Sulindac and
NS-398 Treatment in RhoAQL-expressing Cells and
Is Necessary for Cell Proliferation
Several works have shown that different NSAIDs elicit their
antiinflammatory and antitumoral effects by COX-2–inde-
pendent mechanisms (Tegeder et al., 2001). In fact, sulindac
and NS-398 have been shown to affect NF-B activity as well
as other proteins in different cell types that would account
for some of their specific effects (Yamamoto et al., 1999; Shao
et al., 2000; Mack et al., 2001). This is of particular interest in
our system where both proteins, COX-2 and NF-B, are
directly connected. Thus we sought to determine the effect of
sulindac and NS-398 treatment on NF-B activity under
RhoAQL signaling. To that end, two RhoAQL expressing
clones, SP7.3 and SP7.29, were treated with sulindac (400
M) or NS-398 (150 M) for 72 h, and DNA-binding of
NF-B studied using a B consensus element. As shown in
Figure 7A, NF-B DNA-binding was significantly impaired
upon treatment with both drugs. Accordingly, the level of
nuclear p65 subunit was verified to be lower in treated
versus untreated cells. Whole cell lysates were obtained
under the same conditions and the total level of cellular p65
was determined to remain constant (Figure 7A). Thus, inhi-
bition of NF-B by sulindac and NS-398 is not due to re-
duced NF-B synthesis but rather to a specific inhibition of
its nuclear migration and DNA-binding activity.
Expression of COX-2 by RhoAQL is dependent on NF-B.
Therefore, we hypothesized that inhibition of NF-B upon
sulindac and NS-398 treatment would lead to a reduction in
the level of expressed COX-2. Whole cell extracts were ob-
tained from SP7.3 and SP7.29 cells treated during 24 h with
400 M sulindac or 150 M NS-398, and COX-2 expression
was determined by Western immunoblotting (Figure 7B).
Interestingly, the level of COX-2 was significantly reduced
in sulindac-treated cells and complete loss of expression was
Figure 6. NS-398 inhibits tumor
growth of RhoAQL-transformed
MDCK cells. (A) NS-398 inhibits tu-
mor growth promoted by oncogenic
RhoA. Cells (2  106) were inocu-
lated subcutaneously in nu/nu mice
and when tumors had reached a
mean volume of 0.05–0.1 cm3, mice
were treated intraperitoneally with
NS-398 (3 mg/kg body weight) at
3-d intervals. Statistical significance
was achieved at day 8 of treatment
and was maintained throughout the
rest of the treatment (p  0.05). (B)
Representative pictures of NS398-
treated and vehicle-treated mice in-
oculated with MDCK-RhoAQL cells
at 2 wk of treatment. (C) Inhibition of
Cdc42 in HT29 cells results in a 50%
reduction of anchorage-independent
growth in soft agar. Clones were
stained with crystal violet and were
quantified 1 mo after seeding of cells.
(D) Tumor growth of HT29-
Cdc42N17 (SP1.19) in syngeneic
mice is delayed with respect to
empty vector transfected cells HT29
cells (SP1.7). Cells (2 106; SP1.7 and
SP1.19) were inoculated subcutane-
ously in immunosuppressed mice
and tumor volume was monitored at
2-d intervals. All experiments shown
were performed three independent
times with similar results.
S.A. Benitah et al.
Molecular Biology of the Cell3050
observed upon NS-398 treatment. This effect was not due to
a general loss of expression of cellular proteins because the
level of endogenous p65 was unaffected upon treatment
with both drugs. A similar effect was observed with 50 M
NS-398, although the effect was not as drastic (our unpub-
lished data). Thus, both sulindac and NS-398 affect both
COX-2 and NF-B activities.
Last, we verified whether treatment of MDCK-pcDNAIIB
and MDCK-RhoAQL cells with a specific inhibitor of NF-B,
termed Bay11-7083, would confirm these results. As shown
in Figure 7C, treatment of RhoAQL-expressing cells with
Bay11-7083 resulted in inhibition of both COX-2 expression
and NF-B DNA-binding. We next verified if exposure of
MDCK-RhoAQL cells to Bay11-7083 would lead to inhibi-
Figure 7. Sulindac and NS-398
inhibit both NF-B DNA-binding
and COX-2 expression induced
by RhoAQL. (A) Sulindac and
NS-398 inhibit NF-B DNA-bind-
ing without affecting p65 expres-
sion. MDCK-RhoQL cells (clones
SP7.3 and SP7.29) were treated
with NS-398 and sulindac at the
indicated concentrations for 72 h,
and nuclear and whole cell ex-
tracts were obtained. EMSA anal-
ysis was carried out using a B
consensus sequence, and p65 ex-
pression was verified using an
anti-p65 antibody. (B) Sulindac
and NS-398 treatment inhibit
COX-2 expression induced by
RhoAQL. Same whole cell ex-
tracts as in A were used to verify
COX-2 expression with an anti-
COX-2 antibody. (C) MDCK-
RhoAQL cells (SP7.3) were
treated with Bay11-7083 (10 M)
for 72 h and nuclear and whole
cell extracts were obtained.
EMSA analysis and COX-2 ex-
pression were performed as in A
and B. (D) Bay11-7083 inhibits
MDCK-RhoAQL cell prolifera-
tion with a minor effect over
empty vector transfected MDCK
cells. MDCK-pcDNAIIIb and
MDCK-RhoAQL cells were
plated on 24-well dishes and
were treated with Bay11-7083 (10
M) at the indicated time points.
Cell viability was determined by
the crystal violet method. (E)
Bay11-7083 does not affect the en-
zymatic activity of COX-2 (PGE2
production) in MDCK cells trans-
formed with RhoAQL. MDKC-
pcDNAIIIb and MDCK-RhoAQL
(SP7.3) were plated in 24-well
dishes and were treated with
Bay11-7083 (10 M) for the indi-
cated period of time (0, 6, 8, and
24 h). Supernatant was collected
and PGE2 concentration was
measured as described in MATE-
RIALS AND METHODS. As a
positive control, NS-398 (100 M)
was added for 8 h and PGE2 syn-
thesis was measured as described
above. Ordinate indicate fold induction of PGE2 relative to control cells. (F) Bay11-7083 inhibits RhoAQL-induced COX-2 expression in
MDCK cells at 12 h of treatment. The same experiment as in E was carried in parallel and whole cell extracts were obtained and subjected
to Western blot analysis by using an anti-COX-2 antibody. All experiments were performed three times with similar results.
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tion of cell proliferation. MDCK-pcDNAIIIb and MDCK-
RhoAQL cells were treated with Bay11-7083 (10 M) during
96 h, and cell viability was measured at 24-h intervals (Fig-
ure 7D). Although treatment of MDCK cells with Bay11-7083
produced an inhibition of cell proliferation, this inhibition
was drastically increased in MDCK-RhoAQL cells. Thus,
inhibition of NF-B with Bay11-708 drastically interferes
with cell proliferation driven by oncogenic RhoA, in keeping
with the results shown above on a similar effect induced by
the COX-2 inhibitors sulindac and NS-398.
To discriminate the effects on NF-B from those of COX-2,
we next analyzed the possible inhibitory effect of Bay11-7083
directly on COX-2 activity at early stages of treatment (Fig-
ure 7E). For this, we measured synthesis of PGE2 in both
MDCK control cells (transfected with the empty vector) and
in RhoAQL transformed cells. Bay11-7083 had no significant
effect on COX-2 activity up to 8 h of treatment, whereas a
partial inhibition of PGE2 production could be observed at
12 h of treatment. This effect was due to inhibition of COX-2
expression rather than a direct inhibition over its enzymatic
activity (Figure 7F). As well, as a positive control we treated
MDCK-RhoAQL cells with NS-398 (100 M) for 8 h in the
same experiment and verified that there was a much more
efficient inhibition of COX-2 enzymatic activity. Thus, NF-B
activity is necessary for cell proliferation induced by RhoA.
DISCUSSION
An emerging interest in Rho GTPases signaling as plausible
targets for the development of antitumoral strategies is a
consequence of the overwhelming evidence that relates the
overexpression of either the GTPase itself or the deregula-
tion of some downstream signaling component in a high
number of human cancers (Aznar and Lacal, 2001, 2003;
Sahai and Marshall, 2002). Many works have delineated the
downstream effectors to RhoA, Rac1, and Cdc42 that con-
tribute to the tumoral phenotype. On the other hand, there is
a significant lack of knowledge about the physiological tar-
get genes whose expression is modulated under persistent
Rho signaling contributing to tumor development and me-
tastasis. In this sense, cyclin D1, c-Myc, p21 (Cip1), and p27
(Kip1) are among the few known targets that might enable
aberrant growth stimulated by Rho GTPases (Pruitt and Der,
2001).
In this work, we identify COX-2 as a target gene that is
transcriptionally regulated by Rho GTPases in several cell
lines of murine, canine, and human origin. Activation of
COX-2 by Rho GTPases may be cell specific, as many other
Rho-dependent signaling pathways (reviewed in Aznar and
Lacal, 2001b). Thus, overexpression of COX-2 in human
colon cancer HT29 cells is completely dependent on Cdc42,
because stable expression of dominant negative Cdc42N17
led to complete loss of COX-2 expression. However, al-
though transient expression of oncogenic RhoAQL or
Rac1QL in HT29 results in an increase in COX-2 expression,
inhibition of endogenous Rac1 or RhoA through expression
of their dominant negative inhibitory mutants did not affect
COX-2 expression in the cell line. However, DLD1 cells that
express low levels of Rho GTPases and completely lack
endogenous COX-2 expression, express COX-2 upon RhoA,
but not Rac1 and Cdc42 overexpression. These results sug-
gest that Rho GTPases might be involved in the expression
of COX-2 in a cell type- and tumor-specific manner.
Some works had previously suggested that Rho GTPases
might trigger transcription of the cox-2 promoter, with re-
porter assays and chemical inhibitor experiments (Slice et al.,
1999, 2000; Hahn et al., 2002). Slice et al. (2000) have shown
that RhoA and Rac1 but not Cdc42 induce transcriptional
activation of a reporter vector that contains the cox-2 pro-
moter region spanning from 963 to 50 in NIH3T3 fibro-
blasts. Herein, we provide evidence that either wild-type or
constitutively active forms of Cdc42 stimulate expression of
endogenous COX-2 via the NF-B pathway to a similar
extent to that found for RhoA and Rac1. This discrepancy
might be due to differences in the selected promoter region
used for the reporter vector, because it lacked all putative B
elements present in the endogenous cox-2 promoter. Inter-
estingly, in the same work it was determined that the ele-
ments located in the cox-2 promoter between 80 and 40
were critical for Rac- and Rho-induced transcription of the
reporter vector. In addition, a CRE/ATF element was shown
to be essential for transcriptional stimulation of the reporter
by Rac1, but not for RhoA. In our work, we have observed
that inhibition of NF-B leads to complete loss of COX-2
expression. Although, this does not exclude the possibility
that other cis-acting elements might be relevant for the phys-
iological expression of COX-2 under Rho signaling. Interest-
ingly, although Stat3 is involved in Rho-mediated anchorage
independent growth, and the cox-2 promoter contains at
least two STAT putative binding elements, we have not
observed any effect of Stat3 signaling over Rho GTPases-
induced expression of COX-2.
In terms of the molecular mechanism involved, we have
identified ROCK as one of the RhoA effector proteins in-
volved in the expression of COX-2. The role of ROCK in
Rho-mediated tumorigenesis has been extensively studied.
However, besides their profound effects over cell cytoarchi-
tecture and motility, both of which have been related to its
capability to promote tumor invasion, little is known as to
whether this family of kinases regulates transcriptional
pathways that promote tumor growth. Herein, we demon-
strate that ROCK is necessary for RhoA-induced expression
of COX-2 at the transcriptional level and that ROCK mod-
ulates the transcriptional activity of NF-B.
In keeping with the possible functional relationship be-
tween Rho GTPases and COX-2, there are many similarities
between the expression profiles of both proteins in human
tumors. For instance, both proteins are up-regulated and
necessary for aberrant epidermal growth factor receptor sig-
naling and tumor growth induced by the receptor. The same
holds true for tumor growth induced by oncogenic Ras,
activation of c-Myc by growth factors, or signaling from the
PI3K/Akt pathway (Taylor et al., 2000; Sheng et al., 2001a,b;
Murga et al., 2002; Pai et al., 2002). Furthermore, overexpres-
sion of COX-2 and members of the family of Rho GTPases
has been detected in same human tumors such as breast,
colon, pancreas, and head and neck squamous carcinomas.
The relationship between the NF-B/COX-2 pathway and
Rho proteins in neoplastic transformation might provide an
additional way to treat tumors where Rho proteins are im-
plicated. Several inhibitors of Rho signaling are available
that exhibit antitumoral and antimetastatic activities (Aznar
and Lacal, 2001b, 2003). In identifying the ROCK/NF-B/
COX-2 pathway as a physiological Rho target, new antitu-
moral approaches can be made with respect to tumors
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where Rho GTPases are an issue. MDCK cells transformed
with RhoA, which are tumorigenic as determined by anchor-
age-independent growth and in vivo tumor growth studies,
are susceptible to efficient inhibition of proliferation by su-
lindac and NS-398. Thus, NSAIDs inhibit cell proliferation,
induce apoptosis, and prevent tumor growth of cells trans-
formed with Rho proteins with little effects over parental
untransformed cells. The differences between MDCK and
MDCK-RhoAQL cells upon NSAIDs treatment are probably
due to the differential activities of signaling pathways, in-
cluding COX-2 and NF-B. Indeed, the inhibitory effects of
both NSAIDs over Rho-transformants cannot be solely re-
lated to COX-2 inhibition, because both drugs have been
reported to affect several other pathways (Tegeder et al.,
2001). These pathways regulated by Rho would presumably
set the different behavior of the parental cells versus RhoA-
transformed cells upon drug exposure. Of particular interest
is the inhibitory action of sulindac and NS-398 over NF-B
activation. More importantly, COX-2 expression is com-
pletely inhibited upon 24 h of NS-398 treatment of the cells.
Thus, given that the half-life of COX-2 ranges from 3.5 to 8 h,
the antitumoral effect of both NSAIDs over RhoAQL trans-
formed cells might take place via inhibition of the preexist-
ing COX-2 at early stages of treatment and to sustained
NF-B inhibition during early and late stages of the treat-
ment. This idea is further strengthened by the fact that
BAY11-7083, an inhibitor of NF-B, drastically blocks pro-
liferation of RhoAQL transformed cells with no direct effect
on COX-2 enzymatic activity upon early stages of treatment.
In addition, these observations suggest that treatment of
tumors induced by Rho GTPases with conventional NSAIDs
might be equally valid with respect to treatment with yet to
be synthesized specific COX-2 inhibitors.
Last, we have provided evidence that inhibition of endo-
genously overexpressed Cdc42 in HT29 cells leads to a sig-
nificant delay of tumor growth in vivo, further potentiating
the knowledge of an important role of Rho GTPases in
human cancer. Thus, overall, these results suggest that in-
hibition of Rho GTPases signaling via COX-2, NF-B, or
ROCK may constitute a plausible strategy to inhibit tumor
growth and open a new alley for the development of a novel
antitumoral strategy against human tumors where Rho
GTPases play an important role.
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